Phase II trial of APL-1202 in patients with high risk non-muscle-invasive bladder cancer patients

Trial Profile

Phase II trial of APL-1202 in patients with high risk non-muscle-invasive bladder cancer patients

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs APL 1202 (Primary)
  • Indications Bladder cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Asieris Pharmaceuticals
  • Most Recent Events

    • 27 Dec 2017 Status changed from active, no longer recruiting to completed according to an Asieris Pharmaceuticals media release.
    • 27 Dec 2017 According to an Asieris Pharmaceuticals media release, results from this trial have been presented at the 2017 Bladder Cancer Research Symposium organized by the Albert Institute and MD Anderson Cancer Center, and at the 2017 Annual Meeting of Chinese Society of Clinical oncology (CSCO).
    • 03 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top